In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Quintessential Specialty Pharma, Valeant Embodies PE Tenets

Executive Summary

Even as private equity firms reach into specialty pharma niche opportunities for deals, specialty pharma companies are evolving, as well. Valeant Pharmaceuticals is a very visible example of one kind of specialty pharma model, which is based as much upon sophisticated financial engineering as product growth.

Advertisement

Related Content

Private Equity Reinvents Its Take On Biopharma
Acquisitive Valeant Sheds Staff As It Closes Bausch & Lomb Deal
With Integration of Biovail Nearly Completed, Valeant Looks For More Deals In 2011
Tax Benefits Highlight Announced Merger Of Valeant And Biovail

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004103

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel